Mihail Obrocea, MD
Abbott
5
0
2
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Zhaohui Zhu, MD
Peking Union Medical College Hospital
Shared therapeutic areas:
E-mail: ClinicalTrials@ ImClone.com
Eli Lilly and Company
Shared therapeutic areas:
Project Leader
Ono Pharmaceutical Co., Ltd.
Shared therapeutic areas:
David S Schrump, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Toshimitsu Tokimoto
Astrazeneca KK
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)
All 5 trials loaded